Brain

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study…

10 months ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty…

10 months ago

Linus Health Achieves Landmark Research Recognition Across Peer-Reviewed Medical and Scientific Journals

Research validates the efficacy and accuracy of its digital solutions designed to detect early indicators of cognitive impairment BOSTON, March…

10 months ago

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a…

10 months ago

Business Plan Contest “Photonics Challenge 2025” was Successfully Held in Hamamatsu City, the Center of the Optical Industry

Three companies with outstanding optical technology – Beyond Optical Medical Technologies, Ectobrain Devices and Catana Corporation – presented groundbreaking ideas and…

10 months ago

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily…

10 months ago

Protega Pharmaceuticals collaborates with Wellgistics Health to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond™, is designed to provide multiple levels of protection PRINCETON, N.J., March 3, 2025…

10 months ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids,…

10 months ago